A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam.

Autor: Van Anglen LJ; Healix Infusion Therapy, LLC, Sugar Land, Texas, USA., Schroeder CP; Healix Infusion Therapy, LLC, Sugar Land, Texas, USA., Couch KA; Healix Infusion Therapy, LLC, Sugar Land, Texas, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2023 Mar 28; Vol. 10 (5), pp. ofad173. Date of Electronic Publication: 2023 Mar 28 (Print Publication: 2023).
DOI: 10.1093/ofid/ofad173
Abstrakt: Background: Ceftolozane/tazobactam (C/T) is indicated for the treatment of complicated intra-abdominal infection (IAI), complicated urinary tract infection (UTI), and hospital-acquired/ventilator-associated bacterial pneumonia caused by susceptible bacteria. As real-world data are limited, we report utilization and associated outcomes of C/T use in the outpatient setting.
Methods: This is a multicenter, retrospective study of patients who received C/T between May 2015 and December 2020. Demographics, infection types, C/T utilization characteristics, microbiology, and health care resource utilization were collected. Clinical success was defined as complete or partial symptom resolution at completion of C/T. Persistent infection and discontinuation of C/T were deemed nonsuccess. Logistic regression analysis was used to identify predictors associated with clinical outcomes.
Results: A total of 126 patients (median age, 59 years; 59% male; median Charlson index, 5) from 33 office infusion centers were identified. Infection types included 27% bone and joint infection (BJI), 23% UTI, 18% respiratory tract infection (RTI), 16% IAI, 13% complicated skin and soft tissue infection (cSSTI), and 3% bacteremia. The median daily dose of C/T was 4.5 g, primarily administered via elastomeric pumps as intermittent infusion. The most common gram-negative pathogen was P. aeruginosa (63%), 66% of which was multidrug-resistant and 45% carbapenem-resistant. Enterobacterales was identified in 26% of isolates, of which 44% were extended-spectrum beta-lactamase producers. The overall clinical success rate of C/T was 84.7%. Nonsuccessful outcomes were due to persistent infections (9.7%) and drug discontinuations (5.6%).
Conclusions: C/T was successfully used in the outpatient setting to treat a variety of serious infections with a high prevalence of resistant pathogens.
Competing Interests: Potential conflicts of interest. L.J.V. received grant funding from Merck & Co, Inc., Kenilworth, NJ, USA. All other authors report no potential conflicts.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje